- $3.45bn
- $3.08bn
- $379.81m
US RESEARCH ROUNDUP-Analog Devices, IBM, Qualcomm
CareDx Inc reports results for the quarter ended June 30 - Earnings Summary
CareDx Q2 revenue beats estimates; outlook lifted
Brief: CareDx Q2 Adjusted EPS USD 0.37 Vs. IBES Estimate USD 0.23
U.S. RESEARCH ROUNDUP-Alphabet, IBM, Tesla
U.S. RESEARCH ROUNDUP-IBM, MSCI, US Bancorp
Brief: Caredx Completes Acquisition Of Naveris, Extending Leadership Into High-Growth Specialty Oncology
U.S. Supreme Court rejects CareDx appeal in Natera false-advertising dispute (updated)
Corrected: U.S. Supreme Court rejects CareDx appeal in Natera false-advertising dispute
U.S. Supreme Court rejects Natera, CareDx false-advertising dispute
Brief: Caredx Announces Dismissal Of 2021 Qui Tam Suit
CareDx Q1 revenue rises 39%, beats estimates
Brief: CareDx Q1 Adjusted EPS USD 0.34 Vs. IBES Estimate USD 0.13
Brief: Caredx Announces Agreement To Divest Lab Products Business To Eurobio Scientific For $170 Million And Announces First Quarter Preliminary Financial Results
Brief: Caredx Inc Says Keith Kennedy Appointed As CFO And COO - SEC Filing
Brief: CareDx Announces Appointment of Keith Kennedy as Chief Operating Officer and Chief Financial Officer
CareDx misses Q4 adjusted EPS estimates
CareDx's prelim Q4 revenue beats estimates on higher testing volumes
Brief: CareDx Provides Notice Of Proposed Derivative Settlement